Pharmacokinetics and Pharmacodynamics of Cefepime in Adults with Hematological Malignancies and Febrile Neutropenia after Chemotherapy
Patients with chemotherapy-induced febrile neutropenia (CIFN) may have changes in the pharmacokinetics (PK) compared to patients without malignancies or neutropenia. Those changes in antibiotic PK could lead to negative outcomes for patients if the therapy is not adequately adjusted to this. In this...
Main Authors: | José C. Álvarez, Sonia I. Cuervo, Edelberto Silva, Jorge A. Díaz, Lorena L. Jiménez, Daniel S. Parra, Julio C. Gómez, Ricardo Sánchez, Jorge A. Cortés |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-04-01
|
Series: | Antibiotics |
Subjects: | |
Online Access: | https://www.mdpi.com/2079-6382/10/5/504 |
Similar Items
-
Use of cefepime, meropenem, or piperacillin/tazobactam as initial treatment for febrile neutropenia in patients with hematological malignancy — a real-life experience
by: Najmul Karim, et al.
Published: (2022-08-01) -
Cefepime-Induced Neutropenia: A Case Report and Literature Review
by: Koraysh S, et al.
Published: (2023-04-01) -
A meta-analysis of piperacillin/tazobactam versus cefepime treatment in cancer patients with febrile neutropenia
by: Zhang Weidong, et al.
Published: (2016-12-01) -
Evaluation of Febrile Neutropenia in Hematologic Malignancy Patients
by: Müge ASLAN, et al.
Published: (2014-12-01) -
A physiologically based pharmacokinetic model of cefepime to predict its pharmacokinetics in healthy, pediatric and disease populations
by: Muhammad Talha Zahid, et al.
Published: (2023-08-01)